Study of a new drug for blood cancers that have returned
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This study tests an experimental drug called S241656, either alone or with another medication, for people with certain blood cancers (AML, MDS/AML, or CMML) that haven't responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML), MDS/AML, or chronic myelomonocytic leukemia (CMML) that came back or didn't go away after standard treatment.
- You are generally able to care for yourself (up and about, not bedridden).
- Your kidneys, liver, and heart function are within acceptable limits.
- You haven't had major surgery in the last 4 weeks, and you're recovered from previous treatment side effects.
- You're not pregnant or breastfeeding, and you can take oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
This trial is testing a new medicine called AMX-883 for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk blood disorder called myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. The study hopes to see if the drug is safe and works, either alone or combined with another drug.
This study tests a new drug, S243249, for adults with certain types of acute leukemia that have come back or not responded to treatment. The drug targets changes in the leukemia cells, which may help control the disease.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.